2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2023
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations
Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.Peer-Reviewed Original ResearchConceptsHigher PSA levelsNonmetastatic prostate cancerLocal therapyRadical prostatectomyPSA levelsOverall survivalProstate cancerGood long-term oncological outcomesHigher prostate-specific antigen levelLong-term oncological outcomesProstate-specific antigen levelProstate-specific antigen concentrationCS estimatesInitial local therapyRadical local therapyUnderwent radical prostatectomyEnd Results (SEER) databaseKaplan-Meier methodLong-term outcomesIndependent prognostic valueISUP grade groupCox proportional hazardsImproved CSSPrimary radiotherapyOncological outcomes